Akebia Therapeutics (NASDAQ:AKBA) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.
Insider and Institutional Ownership
69.0% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 2.6% of Akebia Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Akebia Therapeutics and BioLineRx's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Akebia Therapeutics | -126.86% | -68.51% | -34.01% |
BioLineRx | N/A | -96.27% | -55.87% |
Volatility and Risk
Akebia Therapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.
Earnings and Valuation
This table compares Akebia Therapeutics and BioLineRx's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Akebia Therapeutics | $335 million | 1.39 | $-279,660,000.00 | ($1.63) | -1.86 |
BioLineRx | N/A | N/A | $-25,450,000.00 | ($2.55) | -1.08 |
BioLineRx has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Akebia Therapeutics and BioLineRx, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Akebia Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
BioLineRx | 0 | 0 | 2 | 0 | 3.00 |
Akebia Therapeutics currently has a consensus price target of $9.6250, suggesting a potential upside of 217.66%. BioLineRx has a consensus price target of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's stronger consensus rating and higher probable upside, analysts clearly believe BioLineRx is more favorable than Akebia Therapeutics.
Summary
Akebia Therapeutics beats BioLineRx on 9 of the 13 factors compared between the two stocks.